The charts on this page feature a breakdown of the total annual pay for the top executives at SIO GENE THERAPIES INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SIO GENE THERAPIES INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SIO GENE THERAPIES INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Pavan Cheruvu M.D.
Former Chief Executive Officer
Total Cash $475,453 Equity $1,411,600 Other $13,911 Total Compensation $1,900,964
Gavin Corcoran M.D.
Former Chief R&D Officer
Total Cash $276,287 Equity $505,577 Other $11,042 Total Compensation $792,906
David Nassif J.D.
Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer and General Counsel
Total Cash $680,350 Equity $917,654 Other $19,169 Total Compensation $1,617,173
For its 2019 fiscal year, SIO GENE THERAPIES INC, listed the following board members on its annual proxy statement to the SEC.
Atul Pande, M.D. Total Cash $256,603
Berndt Modig Total Cash $232,474
Frank Torti Total Cash $249,603
George Bickerstaff Total Cash $264,342
Myrtle Potter Total Cash $213,316
Roger Jeffs Total Cash $195,055
Senthil Sundaram Total Cash $114,389

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.